EXEL vs GILD
Exelixis vs Gilead Sciences — AI-powered side-by-side comparison
VS
GILD
Gilead Sciences
64
Buy
| Metric | EXEL | GILD |
|---|
| AI Score |
67
|
64
|
| Price |
$52.96
|
$133.10
|
| P/E Ratio |
16.43×
|
-51.23×
|
| ROE |
36.2%
|
37.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
79.6%
|
| Debt / Equity |
0.09×
|
0.21×
|
| Dividend Yield |
0.0%
|
2.4%
|
| RSI (14) |
45.7
|
54.4
|
| Beta |
0.422
|
0.336
|
| Expected Upside |
+6.4%
|
+18.2%
|
AI Committee View
Current Innellis committee reasoning for EXEL versus GILD.
EXEL leads by 3 points.
EXEL scores 67/100 (Buy) versus GILD at 64/100 (Buy).
EXEL Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
GILD Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical